研報掘金丨天風證券:首予舒泰神“買入”評級,看好公司進入加速發展階段
天風證券研報指出,舒泰神深耕治療性藥物領域二十餘載,研發及銷售管線豐富。看好公司進入加速發展階段,首次覆蓋,給予“買入”評級。公司自主研製開發了國家1 類新藥——注射用鼠神經生長因子“蘇肽生”和同時具有清腸和便祕兩個適應症的清腸便祕類藥物——聚乙二醇電解質散劑“舒泰清”。在研血友病新藥獲得突破性療法認定,已提交附條件上市申請公司核心在研品種注射用STSP-0601(通用名:波米泰酶α)凝血因子X激活劑,目前有兩個適應症處於臨牀研究階段,分別是伴抑制物血友病患者按需治療和不伴抑制物血友病患者按需治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.